VERTEX PHARMA - Faltering Pipeline and Sales - a new market research report on companiesandmarkets.com
PR-Inside.com: 2014-03-14 08:32:03
Vertex Pharma (VRTX) 4Q12/FY12 earnings and FY13 guidance (total revenue: $1.1b to $1.25b, ~20% de-growth over FY12) was not a surprise and VRTX is banking on success of its Cystic Fibrosis (CF) drugs in the pipeline for resurrection. VRTX endeavors could be too late in competing from "IFN free oral options" pipeline and uncertainty around combination drugs´ KALYDECO/VX-809 (CFTR Potentiator, PhII) ability to tap the larger CF market (del 508 mutation) could keep the stock volatile in 2013. VX-509 (PhIIb, RA, JAK 3 inhibitor) could attract partnership only if it shows...
For more detail, please read our report released on 31st January, 2013 on Vertex titled "Faltering Pipeline and Sales"
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.